In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Ki: 9.36 and 13.1 nM for chymotrypsin and chymase, respectively
Chymostatin is a chymotryptase-like serine proteases inhibitor.
Serine proteases are enzymes cleaving peptide bonds, in which serine plays as the nucleophilic amino acid. Serine proteases can be classfied into two broad categories: chymotrypsin-like (trypsin-like) or subtilisin-like.
In vitro: Chymostatin was found to be a potent inhibitor of human leucocyte chymotrypsin-like protease. Its affinity to the leucocyte protease was found to be much higher than its affinity to bovine pancreatic alpha-chymotrypsin. Chymsotatin also showed a weak inhibitory effect on the activity of human leucocyte elastase. In addition, the preincubation of chymostatin with 35SO2-4-labeled cartilage before the addition of the human chymotrypsin-like protease to the tissue could also inhibit 35SO2-4 release .
In vivo: The effect of chymostatin on C57BL/6J-dy dystrophic mice was studied. The locomotor activity of normal mice markedly increased, attaining a plateau at 8 weeks of age. Serum levels of creatine phosphokinase were much higher in dystrophic mice when compared with normal mice, and dystrophic mice also showed a reduced muscle protein content. When 3-week-old dystrophic mice received chymostatin at 1 mg/kg, the decrease in locomotor activity could be retarded, serum enzyme levels significantly decreased, and muscle protein content also obviously increased. In addition, the survival time of chymostatin-treated dystrophic mice was prolonged .
Clinical trial: So far, no clinical study has been conducted.
 Feinstein, G. ,Malemud, C.J., and Janoff, A. The inhibition of human leucocyte elastase and chymotrypsin-like protease by elastatinal and chymostatin. Biochim.Biophys.Acta. 429(3), 925-932 (1976).
 Komatsu K, Matsui A, Satoh S. Beneficial effect of chymostatin on dystrophic mice. Exp Neurol. 1986 Jul;93(1):110-6.
|Physical Appearance||A crystalline solid|
|Storage||Store at -20°C|
|Solubility||≤10mg/ml in DMSO|
|Chemical Name||(2R,6R,9R,12R)-6-((R)-2-amino-3,4,5,6-tetrahydropyrimidin-4-yl)-2,12-dibenzyl-9-isobutyl-4,7,10,13-tetraoxo-3,5,8,11-tetraazatridecan-1-oic acid|
|Canonical SMILES||O=C(O)[[email protected]](NC(N[[email protected]]([[email protected]]1CCN=C(N)N1)C(N[[email protected]](CC(C)C)C(N[[email protected]](CC2=CC=CC=C2)C=O)=O)=O)=O)CC3=CC=CC=C3|
|Shipping Condition||Evaluation sample solution: ship with blue ice. All other available sizes: ship with RT, or blue ice upon request.|
|General tips||For obtaining a higher solubility, please warm the tube at 37°C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.|